Literature DB >> 9214432

Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis.

J T Merrill1, C Shen, D Schreibman, D Coffey, O Zakharenko, R Fisher, R G Lahita, J Salmon, B N Cronstein.   

Abstract

OBJECTIVE: To determine why methotrexate (MTX) exacerbates rheumatoid nodules in some patients, despite the effective suppression of synovial inflammation.
METHODS: Phorbol myristate acetate (PMA)-induced differentiation of monocytes into multinucleated giant cells was used as an in vitro model to study the effects of adenosine on nodulosis.
RESULTS: MTX at 200-2,000 nM or the adenosine A1 agonist N5-cyclopentyl adenosine (CPA) (10(-12) to 10(-9) M) or the A2 antagonist 3,7-dimethyl-1-propargylxanthine markedly enhanced giant cell formation, whereas the adenosine A1 antagonist 8-cyclopentyl-dipropylxanthine completely reversed these effects. PMA, CPA, and MTX induced adenosine release by cultured monocytes at concentrations consistent with those associated with predominantly A1 effects. Furthermore, surface expression of A1 receptors was found to remain unchanged on the differentiating cells throughout the culture period.
CONCLUSION: Agents that inhibit adenosine A1 receptors might be useful in the treatment of MTX-induced rheumatoid nodulosis, while still potentiating the A2-mediated antiinflammatory effects of MTX on synovitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9214432     DOI: 10.1002/1529-0131(199707)40:7<1308::AID-ART16>3.0.CO;2-M

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  48 in total

Review 1.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis.

Authors:  M Cutolo; A Sulli; C Pizzorni; B Seriolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

2.  Adenosine A2A receptor activation prevents wear particle-induced osteolysis.

Authors:  Aránzazu Mediero; Sally R Frenkel; Tuere Wilder; Wenjie He; Amitabha Mazumder; Bruce N Cronstein
Journal:  Sci Transl Med       Date:  2012-05-23       Impact factor: 17.956

3.  Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling.

Authors:  W He; B N Cronstein
Journal:  Purinergic Signal       Date:  2012-02-05       Impact factor: 3.765

Review 4.  Cutaneous nodules in patients with rheumatoid arthritis: a case report and review of literatures.

Authors:  Tadashi Nakamura; Syu-ichi Higashi; Kunihiko Tomoda; Michishi Tsukano; Ken-ichi Iyama
Journal:  Clin Rheumatol       Date:  2010-11-04       Impact factor: 2.980

5.  PharmGKB summary: methotrexate pathway.

Authors:  Torben S Mikkelsen; Caroline F Thorn; Jun J Yang; Cornelia M Ulrich; Deborah French; Gianluigi Zaza; Henry M Dunnenberger; Sharon Marsh; Howard L McLeod; Kathy Giacomini; Mara L Becker; Roger Gaedigk; James Steven Leeder; Leo Kager; Mary V Relling; William Evans; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

Review 6.  Regulation of macrophage function by adenosine.

Authors:  György Haskó; Pál Pacher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

Review 7.  Methotrexate and its mechanisms of action in inflammatory arthritis.

Authors:  Bruce N Cronstein; Thomas M Aune
Journal:  Nat Rev Rheumatol       Date:  2020-02-17       Impact factor: 20.543

8.  Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules.

Authors:  D Baeten; F De Keyser; E M Veys; Y Theate; F A Houssiau; P Durez
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

Review 9.  Adenosine and bone metabolism.

Authors:  Aránzazu Mediero; Bruce N Cronstein
Journal:  Trends Endocrinol Metab       Date:  2013-03-14       Impact factor: 12.015

10.  Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant.

Authors:  Rebecca L Williams-Karnesky; Mary P Stenzel-Poore
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.